Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes
Authors' conclusion
SYNCHRONIZE-2 will determine the efficacy, safety and tolerability of survodutide for BW reduction in people with obesity and T2D, whose baseline characteristics suggest a representative, diverse cohort.
Study context
- Population
- Adults aged ≥18 years with body mass index (BMI) ≥27 kg/m² and T2D
- Participants
- 752 treated participants
- Comparison
- Weekly subcutaneous survodutide vs placebo
- Primary endpoint
- Percentage change in body weight and achievement of body weight reduction ≥5% from baseline
- Follow-up
- Week 76
Methodological detailsdouble-blind, randomized 1:1:1, global, 133 sites across 19 countries
- Double-blind
- Randomized 1:1:1
- Global
- 133 sites across 19 countries
Primary result
As reported in the abstract
Baseline characteristics
- Mean age
- 55.7 years
- BMI
- 36.5 kg/m²
- Body weight
- 104.1 kg
- Waist circumference
- 115.5 cm
- HbA1c
- 7.4%
- Female
- 50.7%
- From Europe
- 36.2%
- From North America
- 32.8%
- From East Asia
- 22.3%
- Hypertension
- 69.0%
- Dyslipidaemia
- 67.6%
- Obstructive sleep apnoea
- 17.3%
- Arteriosclerotic CVD
- 10.9%
- Treated with metformin
- 78.7%
- Treated with SGLT2i
- 34.2%
- Treated with lipid-lowering medications
- 58.6%
Original publication
Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. Published 11 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →